Everolimus plus exemestane for hormone resistant metastatic breast cancer

Trial Profile

Everolimus plus exemestane for hormone resistant metastatic breast cancer

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Jul 2015

At a glance

  • Drugs Everolimus (Primary) ; Exemestane (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jul 2015 New trial record
    • 02 Jun 2015 23 patients were enrolled between Sep 2012 and Jan 2015, according to the 2015 ASCO abstract.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top